Blood interaction with a Bioline heparin coated HIA-VAD: a study on calves.
The blood compatibility of ventricular assist devices developed by the Helmholtz Institute Aachen (HA-VAD's) was tested on calves. Seven calves received a non-coated HIA-VAD (control) and three a Bioline heparin coated device. The circulatory support of these HIA-VAD's lasted one week. Mechanical blood cell trauma estimated by hematocrit (Hct), hemoglobin (total Hb) and free plasma hemoglobin (free Hb) levels did not differ in either group. All HIA-VAD's in the control group remained thrombus free, except on one occasion when an inflow cannula was obstructed by a thrombus located in the tip. After circulatory support, the animals in this group seemed clinically healthy. However, thrombus formation was observed in the three heparin coated HIA-VAD's. One animal in this group died from complications after re-operation for pneumothorax on the fifth day of support, whereas the other two animals seemed clinically healthy. In these three animals, a strong decrease in platelet numbers was measured even after 24 hours of support which recovered after 72 hours. This decrease in platelet numbers was associated with a lower degree of platelet aggregation ability stimulated by ADP (p < 0.05). Fibrin(ogen) degradation products (FDP) increased significantly immediately after the implantation procedure (p < 0.05). Fibrinogen levels initially decreased during the implantation procedure, but increased thereafter in both groups. The FDP levels remained high in this group, although the FDP levels in both groups were decreased after the implantation procedure. The ex vivo measured circulating heparin levels were lower in the heparin coated HIV-VAD group despite the equally administrated heparin doses in both animal groups. No differences were measured in either group with regard to white blood cell (WBC) numbers and complement hemolytic activity (CH50). Despite these hemostatic changes, no mechanical trauma could be demonstrated after seven days of circulatory support.
van der Kamp
K W
KW
Blood Interaction Research, Thorax Center, University Hospital of Groningen, The Netherlands.
Magielse
C P
CP
Elstrodt
J M
JM
van der Meer
J
J
van Oeveren
W
W
Rakhorst
G
G
D000818:Animals; D000925:Anticoagulants / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D001672:Biocompatible Materials; D001777:Blood Coagulation / Q000187:drug effects; D001798:Blood Proteins / Q000378:metabolism; D002417:Cattle; D015941:Complement Hemolytic Activity Assay; D004912:Erythrocytes / Q000166:cytology / Q000473:pathology; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D006353:Heart-Assist Devices; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism; D006493:Heparin / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D007962:Leukocytes / Q000166:cytology / Q000473:pathology; D009426:Netherlands; D010974:Platelet Aggregation / Q000187:drug effects; D011183:Postoperative Complications / Q000401:mortality; D013923:Thromboembolism / Q000517:prevention & control*
D000925:Anticoagulants; D001672:Biocompatible Materials; D001798:Blood Proteins; D005343:Fibrinolytic Agents; D006454:Hemoglobins; D005340:Fibrinogen; D006493:Heparin